Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807492 | 0.90 | MAP4K4 (0.39) | MAP4K4GPR119MEN1KMT2AMAPK1 | |
| SCHEMBL20593266 | 0.82 | GRM5 (0.34) | ATRATRIP | |
| SCHEMBL20593269 | 0.82 | GRM5 (0.34) | ATRATRIP | |
| SCHEMBL2795279 | 0.79 | P2RX7 (0.41) | MAP4K4GPR119MEN1KMT2AMKNK1 | |
| SCHEMBL31569496 | 0.77 | MEN1 (0.38) | MAP4K4GPR119MEN1KMT2A | |
| SCHEMBL31569051 | 0.77 | MEN1 (0.38) | MAP4K4GPR119MEN1KMT2A | |
| SCHEMBL1329919 | 0.75 | ESR2 (0.48) | MKNK1 | |
| SCHEMBL31548527 | 0.75 | ESR2 (0.48) | MKNK1 | |
| SCHEMBL22715947 | 0.73 | ESR2 (0.43) | MAP4K4GPR119MEN1KMT2AMAPK1 | |
| SCHEMBL21807224 | 0.73 | MAP4K4 (0.38) | MAP4K4GPR119MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | MAP4K4 196/4885GPR119 3577/4885MEN1 3160/4885 |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | MAP4K4 196/4885GPR119 3577/4885MEN1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.